Author: curevovaccine

-- Trial targets enrollment of 640 participants aged 50 and over to receive amezosvatein or Shingrix® Seattle, WA – June 2, 2025 – Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the enrollment of the first patients in a Phase 2 extension trial of its investigational shingles…

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study  -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair Seattle, WA – March 17, 2025 – Curevo Vaccine…

-- One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix Seattle, WA – January 12, 2025 – Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability and accessibility, today announced positive updated immunogenicity and safety data from its 876-patient…

Seattle, WA – January 8, 2025 – Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced it has been selected to present in the Private Company Track at the 43rd Annual J.P. Morgan Healthcare Conference. Curevo’s CEO, George Simeon, will discuss updated data from…

-- Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten shingles cases would have been expected absent vaccination   -- Updated data will be featured in an oral presentation at the World Vaccine Congress Barcelona, 31 October 2024, in Theatre 5 at 13:30 CEST Seattle, WA –…

-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein elicits robust humoral and cellular immune responses with comparatively lower reactogenicity -- Amezosvatein met both primary endpoints of immunogenicity non-inferiority and safety -- Updated data will be presented on poster #597, available October 17th from 12:15 to 1:30pm PDT in Hall J & K Seattle, WA – October 16,…

-- Chi Li, PhD, MBA, RAC adds over 20 years of global regulatory experience and success to the Curevo Vaccine executive team Seattle, WA (Globe Newswire) – April 8, 2024 – Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the…

-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including a 100% vaccine response rate  -- Amezosvatein also met the primary safety endpoint, with lower local and systemic adverse events in this trial compared to Shingrix  -- Amezosvatein to enter global Phase 3 trials in…